Clinical Trial Search

Primary: Response Rate — 0; 0; 1; 0 participants

Primary: Response Rate of ZD1839 in Patients With Advanced or Recurrent Salivary Gland Cancer Who Are Not Candidate for Curative Surgery or Radiotherapy — 0; 0; 18; 13 Participants

Primary: Incidence of Toxicity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 — 3; 1; 2; 6 Participants

Primary: Response Rate — 1; 2; 23; 3 Participants

Primary: Number of Patients Scored as Having the Surgical Technique of Submandibular Salivary Gland Transfer Performed "Per Protocol" — 34 participants

Primary: Best Overall Response Rate — 2; 5; 17; 8 Participants

Primary: Objective Response Rates (Partial and Complete Responses) — 0 participants

Primary: 1-year Local Control — NA; NA months

Primary: the Number of Lymph Nodes: 1. Identified Within Each Lymph Node Group, 2.Located Within the Submandibular Gland, and 3. Within the Fibrofatty Contents Lying Deep to the…

Primary: Incidence of Toxicity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 1; 1; 0; 1 Participants

Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants

Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants

Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants

Primary: Objective Response According to RECIST 1.1 Criteria — 2; 27; 1 Participants

Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants

Primary: Patients Demonstrating Objective Response In Non-Irradiated Lesions (Tumor Size on Scans) — 0; 0 Participants

Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects

Primary: Progression-free Survival (PFS) — 65 percentage of patients

Primary: Survival Rate of Patients — 33 months

Primary: Locoregional Recurrence Rates in Cohorts 1 and 2 — 2; 2 Participants

Primary: Major Pathologic Response — 22 Participants

Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Overall Response Rate — 22.7 percentage

Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants

Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants

Primary: Objective Response Rate — 37.5; 5.9; 0; 16.7 percentage of patients

Primary: Overall Response Rate — 0; 3; 25; 4 Participants

Primary: Disease Specific Survival (DSS) — 29; 15; 15 participants

Primary: Llocoregional Recurrence — 27 Participants